Replies to post #127109 on Biotech Values

[rajaram46]

Great point Tinker. If Amphastar doesn't have the revenue base or will be slowly declining without a-enox, then they have nothing to lose.

To what extent could Watson be on the hook as well?

[DewDiligence]

I do not know what else Amphastar has going for it product and business wise, but if generic enoxaparin is it, look for Amphastar to be reckless..

Amphastar has been around for 15 years and has several marketed products—see http://www.amphastar.com/products.htm .